Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
Sponsored by Novo Nordisk A/S
About this trial
Last updated 8 years ago
Study ID
HGH-2147
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
3 to 13 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 19 years ago
What is this trial about?
This trial is conducted in the United States of America (USA). This is a 12 month study to
determine if Norditropin is safe and effective in children with IGF deficiency.
What are the participation requirements?
Inclusion Criteria
- Ages 3-15
- Presence of growth failure indicated by height standard deviation score less than equal to -2
- Body mass index greater than or equal to 25th percentile for height age
- IGF concentration less than or equal to 33rd percentile